Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 4, 2000, Pages 341-344

  Mavroudis, D ^a   Kourousis, C ^a   Androulakis, N ^a   Kalbakis, K ^a   Agelaki, S ^a   Kakolyris, S ^a   Souglakos, J ^a   Sarra, E ^a   Vardakis, N ^a   Hatzidaki, D ^a   Sarmonis, G ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Advanced gastric cancer; Docetaxel; G CSF

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMACH CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; FEVER; FOLLOW-UP STUDIES; GASTRECTOMY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0034449134     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200008000-00005     Document Type: Article

References (19)

1. Gastric carcinoma
2. Chemotherapy of gastric cancer: A review
3. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer
4. Studies with RP 56976 (Taxotere): A semisynthetic analog of Taxol
5. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo
6. Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial
7. 2 docetaxel with prednisone premedication in patients with advanced non-small cell lung cancer
8. Comprehensive criteria for assessing therapy-induced toxicity
9. Nonparametric estimation from incomplete observations
10. The effect of G-CSF on docetaxel (Taxotere) associated neutropenia during therapy for breast cancer
11. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for breast cancer
12. A late phase II study of docetaxel in patients with gastric cancer
13. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293
14. Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer
15. Phase II study of taxol in patients with gastric carcinoma
16. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer
17. Taxoterecisplatin in advanced gastric carcinoma: An active drug combination